JP2011511810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511810A5 JP2011511810A5 JP2010546107A JP2010546107A JP2011511810A5 JP 2011511810 A5 JP2011511810 A5 JP 2011511810A5 JP 2010546107 A JP2010546107 A JP 2010546107A JP 2010546107 A JP2010546107 A JP 2010546107A JP 2011511810 A5 JP2011511810 A5 JP 2011511810A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- item
- amino
- substituents
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 706
- 150000001875 compounds Chemical class 0.000 claims description 463
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 275
- 125000001424 substituent group Chemical group 0.000 claims description 237
- -1 cyano, hydroxy Chemical group 0.000 claims description 224
- 239000000203 mixture Substances 0.000 claims description 183
- 125000003545 alkoxy group Chemical group 0.000 claims description 142
- 229910052736 halogen Inorganic materials 0.000 claims description 141
- 150000002367 halogens Chemical class 0.000 claims description 141
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 137
- 125000003282 alkyl amino group Chemical group 0.000 claims description 136
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 125
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 125
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 112
- 125000000304 alkynyl group Chemical group 0.000 claims description 99
- 229910052799 carbon Inorganic materials 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 39
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 36
- 229910052731 fluorine Inorganic materials 0.000 claims description 36
- 239000011737 fluorine Substances 0.000 claims description 36
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 23
- 208000012902 Nervous system disease Diseases 0.000 claims description 22
- 208000015114 central nervous system disease Diseases 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 22
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000019901 Anxiety disease Diseases 0.000 claims description 15
- 201000004624 Dermatitis Diseases 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 15
- 208000028017 Psychotic disease Diseases 0.000 claims description 15
- 230000036506 anxiety Effects 0.000 claims description 15
- 230000036528 appetite Effects 0.000 claims description 15
- 235000019789 appetite Nutrition 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- 201000000980 schizophrenia Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 9
- 201000004384 Alopecia Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 8
- 206010012335 Dependence Diseases 0.000 claims description 8
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 8
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 8
- 208000016620 Tourette disease Diseases 0.000 claims description 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 208000024963 hair loss Diseases 0.000 claims description 8
- 230000003676 hair loss Effects 0.000 claims description 8
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 46
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 41
- 238000006467 substitution reaction Methods 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 96
- 235000019000 fluorine Nutrition 0.000 description 80
- 125000001153 fluoro group Chemical group F* 0.000 description 45
- 125000000753 cycloalkyl group Chemical group 0.000 description 24
- 0 *c1c(*N(*)*)c(c(*)ccc2)c2[n]1* Chemical compound *c1c(*N(*)*)c(c(*)ccc2)c2[n]1* 0.000 description 21
- 125000002947 alkylene group Chemical group 0.000 description 18
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 11
- 239000006186 oral dosage form Substances 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2782508P | 2008-02-11 | 2008-02-11 | |
| PCT/US2009/033822 WO2009102805A1 (en) | 2008-02-11 | 2009-02-11 | Indole compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011511810A JP2011511810A (ja) | 2011-04-14 |
| JP2011511810A5 true JP2011511810A5 (https=) | 2012-04-05 |
Family
ID=40445507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546107A Withdrawn JP2011511810A (ja) | 2008-02-11 | 2009-02-11 | インドール化合物およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090318527A1 (https=) |
| EP (1) | EP2254865A1 (https=) |
| JP (1) | JP2011511810A (https=) |
| AU (1) | AU2009214724A1 (https=) |
| CA (1) | CA2715282A1 (https=) |
| WO (1) | WO2009102805A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005300045A1 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| CN102574787B (zh) * | 2009-07-30 | 2014-12-31 | 新加坡国立大学 | 具有潜在的抗癌活性的小分子异戊二烯基半胱氨酸羧基甲基转移酶抑制剂 |
| EP2464227A4 (en) * | 2009-08-10 | 2013-02-20 | Galenea Corp | COMPOUNDS AND METHODS OF USE |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2018064465A1 (en) * | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| CN113784962B (zh) | 2019-02-27 | 2025-04-25 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| EP4219498A1 (en) * | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| CA3160793A1 (en) * | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12343328B2 (en) | 2020-12-09 | 2025-07-01 | Caamtech, Inc. | Dialkyl tryptamines and their therapeutic uses |
| EP4347561A4 (en) * | 2021-05-26 | 2025-08-06 | Bright Minds Biosciences Inc | HETEROCYCLIC COMPOUNDS AND PROCESSES FOR THEIR PREPARATION |
| JP2025501629A (ja) * | 2021-12-24 | 2025-01-22 | サイロ プロプライエタリ リミテッド | 化合物 |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| AU2023307226A1 (en) * | 2022-07-15 | 2025-02-27 | Caamtech, Inc. | Tryptamine derivatives |
| JP2025526785A (ja) * | 2022-08-11 | 2025-08-15 | ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド | トリプタミン及び気分障害を治療する方法 |
| US20260083759A1 (en) | 2022-09-06 | 2026-03-26 | Hadasit Medical Research Services And Development Ltd | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders |
| AU2024309903A1 (en) | 2023-06-28 | 2026-01-08 | Psylo Pty Ltd | Compounds |
| CN121909189A (zh) | 2023-06-28 | 2026-04-21 | 赛洛私人有限公司 | 用于治疗精神疾病的吡咯并吡啶化合物 |
| WO2025099725A1 (en) | 2023-11-09 | 2025-05-15 | Hadasit Medical Research Services And Development Ltd. | Conjugates and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60222396T2 (de) * | 2001-03-29 | 2008-05-15 | Eli Lilly And Co., Indianapolis | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste |
| AU2005300045A1 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
-
2009
- 2009-02-11 EP EP09710775A patent/EP2254865A1/en not_active Withdrawn
- 2009-02-11 US US12/369,659 patent/US20090318527A1/en not_active Abandoned
- 2009-02-11 JP JP2010546107A patent/JP2011511810A/ja not_active Withdrawn
- 2009-02-11 AU AU2009214724A patent/AU2009214724A1/en not_active Abandoned
- 2009-02-11 CA CA2715282A patent/CA2715282A1/en not_active Abandoned
- 2009-02-11 WO PCT/US2009/033822 patent/WO2009102805A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011511810A5 (https=) | ||
| JP2012526842A5 (https=) | ||
| JP2012503008A5 (https=) | ||
| JP2014515008A5 (https=) | ||
| JP2010510976A5 (https=) | ||
| JP2011518218A5 (https=) | ||
| JP2009537469A5 (https=) | ||
| JP2009533410A5 (https=) | ||
| JP2011519854A5 (https=) | ||
| EP4328223A3 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
| JP2008530099A5 (https=) | ||
| JP2013530150A5 (https=) | ||
| JP2013531008A5 (https=) | ||
| JP2014051526A5 (https=) | ||
| JP2010520341A5 (https=) | ||
| JP2015516420A5 (https=) | ||
| JP2012504608A5 (https=) | ||
| JP2009531277A5 (https=) | ||
| JP6452731B2 (ja) | アミノカルボニルカルバメート化合物 | |
| JP2012502111A5 (https=) | ||
| JP2013526610A5 (https=) | ||
| JP2008502683A5 (https=) | ||
| NZ597498A (en) | Cyclopropyl amine derivatives as histamin H3 receptor modulators | |
| JP2004527492A5 (https=) | ||
| JP2006521393A5 (https=) |